TGFB1 was increased in multiple CD3+ subsets including CD4+ TEMRA, CD8+ TEMRA, CD8+ EM, non-VD2 gamma-delta, and VD2 gamma-delta T cells following Foralumab treatment when compared to both healthy controls and untreated COVID-19 subjects. Here, CD4 is linked to COVID-19.